View the slides for the "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy

The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients&Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana Universityá Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient's T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T cells are then reinfused into the body with the hope of fighting the disease. To learn about this exciting new therapy, register for free HERE. Pre-registration is highly recommended.
Source: International Myeloma Foundation - Category: Hematology Source Type: news

Related Links:

Conclusions: Our results suggest that cell fusion between BM-MSCs and MM cells could contribute it genomic heterogeneity and play a role on disease progression. Methods: We fused human BM-MSCs with MM cells lines RPMI 8226 or XG1 in vitro by polyethylene glycol (PEG), and the hybrid cells were sorted by sedimentation assays. The growth, migration, cell cycle, chromosome and drug sensitive of hybrids were assessed by cell counting, cell colony formation, transwell assays, cytogenetic assay and flow cytometry (FCM). The proteins and genes related to stemness and cytokines were tested by western blot and/or real-time quan...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
Conditions:   B-cell Acute Lymphoblastic Leukemia;   Lymphoma;   Myeloid Leukemia;   Multiple Myeloma;   Hepatoma;   Gastric Cancer;   Pancreatic Cancer;   Mesothelioma;   Colorectal Cancer;   Esophagus Cancer;   Lung Cancer;   Glioma;   Melanoma;   Synovial Sarcoma;   Ovarian Cancer ;   Renal Carcinoma Intervention:   Biological: CAR-T cell immunotherapy Sponsors:   Shenzhen BinDeBio Ltd.;   The First Affiliated Hospital of Zhengzhou University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractTumor-mediated immunosuppression via regulatory T-cells is a key player among the various immune-escape mechanisms in multiple myeloma. We analyzed the generation, distribution, function and immunophenotype of CD8+CD28− regulatory T-cells in patients with multiple myeloma. Functionality of CD8+CD28− T-cells was assessed by immunological assays using ex vivo generated antigen-specific T-cells from patients with plasma cell dyscrasias and healthy donors. Detailed analysis of distribution, immunophenotype and cytotoxic potential of CD8+CD28− T-cells was performed by flow cytometry and ELISA. We found...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 August 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Jacqueline C. Barrientos, Susan O'Brien, Jennifer R. Brown, Neil E. Kay, Nishitha M. Reddy, Steven Coutre, Constantine Tam, Stephen Mulligan, Ulrich Jaeger, Stephen Devereux, Christopher Pocock, Tadeusz Robak, Stephen J. Schuster, Anna Schuh, Devinder Gill, Adrian Bloor, Claire Dearden, Carol Moreno, Gavin Cull, Mike HamblinAbstractBackgroundIbrutinib compared with ofatumumab significantly improves progression-free and overall survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic l...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Though survival rates have improved markedly, a variety of problems can cause death.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Leukemia Antibiotics Cancer Multiple Myeloma Bone Marrow Deaths (Fatalities) Longevity Infections Heart Source Type: news
Whole-body MR imaging (WB-MR imaging) has become a modality of choice for detecting bone metastases in multiple cancers, and bone marrow involvement by multiple myeloma or lymphoma. Combination of anatomic and functional sequences imparts an inherently hybrid dimension to this nonirradiating tool and extends the screening of malignancies outside the skeleton. WB-MR imaging outperforms bone scintigraphy and CT and offers an alternative to PET in many tumors by time of lesion detection and assessment of treatment response. Much work has been done to standardize procedures, optimize sequences, validate indications, confirm pr...
Source: PET Clinics - Category: Radiology Authors: Source Type: research
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting novel avenues for multiple myeloma (MM) therapy from the 1st European Myeloma Network (EMN) Meeting, in Turin, It... Author: VJHemOnc Added: 08/16/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses new strategies for clinical trial design in multiple myeloma (MM). Prof. McCarthy highlights measurable residua... Author: VJHemOnc Added: 08/16/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses considerations in the treatment of high risk multiple myeloma (MM) from the 1st European Myeloma Network (EMN) Meeting, in... Author: VJHemOnc Added: 08/16/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses two Phase III multiple myeloma (MM) transplantation studies that have been performed: EMN02 (NCT01208766) and B... Author: VJHemOnc Added: 08/16/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Hematology | Immunotherapy | Learning | Myeloma | Universities & Medical Training | University of Pennsylvania